Glenmark introduces bioequivalent Ropivacaine Hydrochloride Injection in the US, expanding its injectable portfolio and ensuring affordable, high-quality therapeutic alternatives for patients.

• The injection matches Naropin by Fresenius Kabi in terms of bioequivalence and therapeutic standards, with US distribution set to begin in November 2025.
• Naropin Injection market reached $20.9 million in annual US sales for the 12 months ending August 2025.
• Glenmark strengthens its generics and branded medicines portfolio across respiratory, dermatology, and oncology therapeutic segments globally.